Register to receive a free U.S. Market Report Suite for Diagnostic Ophthalmic Devices – MedSuite report synopsis and brochure
Johnson & Johnson’s TECNIS Eyhance intraocular lens has been launched in commercial European markets for cataract treatment. Existing intraocular lenses aim to provide superior vision at distances, and as such, cataract patients would require glasses for performing many common arm-length tasks, such as reading or operating a computer. Described as a next-generation monofocal lens, the TECNIS Eyhance aims to mitigate these flaws by providing quality vision at both far and intermediate distances.
The company claims that the CE-market Eyhance provides 20/20 distance vision and significant improvements for intermediate vision. Patients have reported quality of life improvements from their ability to more easily perform activities such as walking on irregular surfaces or participating in their hobbies.
The TECNIS series, including the TECNIS Eyhance intraocular lens, was acquired by Johnson & Johnson from Abbott’s Medical Optics division in the beginning of 2017, valued at $4.3 billion. The acquisition also included devices for LASIK refractive surgery, contact solutions, and eye drops for dry eyes. This agreement drove Johnson & Johnson’s global vision care sales that year by 45.9%, allowing them to clear the $4 billion mark. This section accounted for 4.5% of the company’s global operational sales growth.
Market research published by iData Research demonstrates that the intraocular lens market is generally driven by the increasing prevalence of cataracts as the population continues to age. Monofocal lenses, such as the TECNIS Eyhance intraocular lens, represent the majority of the U.S. intraocular lens market, but will soon be overtaken by the accommodative intraocular lens segment. Despite this, monofocal lenses remain a common and favorable choice for many patients, especially with the increasing adoption of toric monofocal intraocular lenses. Overall, the monofocal segment is growing at a rate of over 3%, which will continue to increase as the total market is driven.
“We saw an opportunity to build upon the legacy of the TECNIS family of IOLs and the proven design of our one-piece platform to reimagine what was possible with the standard aspheric monofocal IOL,” said Tom Frinzi, president of the worldwide surgical business at J&J Vision.
For Further Information
More on the interventional ophthalmic market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices.
